Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | 10% owner | June 26, 2023 | June 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date June 26, 2023 · Filed June 28, 2023
Jointly reported with Chione Ltd, Czernik Marcin, Hadjimichael Andreas, Smolokowski Wiaczeslaw
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,848,632 |
Reported balance
After 2023-06-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-26 · Sale · Disposed 16 · Balance 3,848,632 F1: The price reported in Column 4 is a weighted average price. The shares referred to in Column 4 were sold at $12.925 and $12.93. F2: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares referred to in Column 4 were sold at $12.925 and $12.93.
F2: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.
F3: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione.
F4: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
F5: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2023 Filed Jun 28, 2023 15:47 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 16 | $12.93 | $206.88 |
DisclosureSEC source: 0001213900-23-052442 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,848,632 F1 · price: The price reported in Column 4 is a weighted average price. The shares referred to in Column 4 were sold at $12.925 and $12.93. F2 · ownership.direct: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 17:15 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 2,056 | $12.14 | $24,959.84 |
DisclosureSEC source: 0001213900-23-050160 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,848,648 F1 · price: The price reported in Column 4 is a weighted average price. The shares referred to in Column 4 were sold at prices ranging from $12.04 to $12.50, inclusive. F2 · ownership.direct: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 18:33 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 893 | $12.13 | $10,832.09 |
DisclosureSEC source: 0001213900-23-049014 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,850,704 F1 · price: The prices reported in Column 4 are weighted average prices. The 2,000 shares referred to in the first row of Column 4 were sold at prices ranging from $12.165 to $12.49, inclusive. The 3,000 shares referred to in the second row of Column 4 were sold at prices ranging from $12.03 to $12.55, inclusive. The 893 shares referred to in the third row of Column 4 were sold at prices ranging from $12.01 T0 $12.47, inclusive. F2 · ownership.direct: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 18:33 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 3,000 | $12.30 | $36,900.00 |
DisclosureSEC source: 0001213900-23-049014 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,851,597 F1 · price: The prices reported in Column 4 are weighted average prices. The 2,000 shares referred to in the first row of Column 4 were sold at prices ranging from $12.165 to $12.49, inclusive. The 3,000 shares referred to in the second row of Column 4 were sold at prices ranging from $12.03 to $12.55, inclusive. The 893 shares referred to in the third row of Column 4 were sold at prices ranging from $12.01 T0 $12.47, inclusive. F2 · ownership.direct: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 18:33 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 2,000 | $12.34 | $24,680.00 |
DisclosureSEC source: 0001213900-23-049014 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,854,597 F1 · price: The prices reported in Column 4 are weighted average prices. The 2,000 shares referred to in the first row of Column 4 were sold at prices ranging from $12.165 to $12.49, inclusive. The 3,000 shares referred to in the second row of Column 4 were sold at prices ranging from $12.03 to $12.55, inclusive. The 893 shares referred to in the third row of Column 4 were sold at prices ranging from $12.01 T0 $12.47, inclusive. F2 · ownership.direct: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionSeries B Preferred Stock · Derivative | 26,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-074313 · ownership.xml · derivative · entry 5 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F2 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). F3 · ownership.direct: Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionSeries A-1 Preferred Stock · Derivative | 8,497,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-074313 · ownership.xml · derivative · entry 4 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,445,940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F2 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). F3 · ownership.direct: Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionCommon Stock | 10,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-074313 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F2 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). F3 · ownership.direct: Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | ConversionCommon Stock | 3,445,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-22-074313 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") was automatically converted into Common Stock on a 2.466 to 1 share basis, without payment of further consideration, in connection with the closing of the issuer's initial public offering. The conversion prices per share of Common Stock for the Series A-1 Preferred Stock and Series B Preferred Stock were $5.6225 and $14.0745, respectively. The Preferred Stock had no expiration date. F2 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). F3 · ownership.direct: Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 18:26 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | PurchaseCommon Stock | 400,000 | $12.50 | $5,000,000.00 |
DisclosureSEC source: 0001213900-22-074313 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Nikolaou Anastasis · CIK 0001954186 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,856,597 F2 · ownership.direct: Shares owned directly by Chione Limited ("Chione"). F3 · ownership.direct: Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione. F4 · ownership.direct: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities. F5 · ownership.direct: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.